STOCKHOLM, Sweden, 14 March 2025
Avia Pharma has entered into an exclusive agreement with Nemysis Limited to introduce Tolfer, a next-generation iron supplement containing IHAT (Iron Hydroxide Adipate Tartrate), to the Nordic market. The partnership aims to provide a well-tolerated and highly bioavailable solution for the prevention and treatment of iron deficiency across the region.
Marie Wikman, Head of Nordics Avia Pharma, states: “We are very excited to bring Tolfer to our markets. We believe this unique product will support many of our customers and strengthen our ability to fulfil our mission of making Northern Europe a healthier place, particularly within our Women’s Health market focus.”
Commenting on the Agreement, Marco Cartolari, Chief Operating Officer Nemysis remarks “We are pleased to add this collection of territories to IHAT’s footprint and that of the Tolfer brand and to be working with a fast-growing partner such as Avia and its team. This collaboration is a robust strategic fit for both parties and we look forward to all stakeholders benefitting from Tolfer in the covered territories”.
Tolfer will be available in pharmacies in Sweden, Finland and Denmark.